WILATE
Biological
Octapharma USA, Inc.
Total Payments
$2.0M
Transactions
432
Doctors
204
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $2.0M | 259 | 139 |
| 2017 | $77,697 | 173 | 80 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 8 | 55.0% |
| Grant | $795,287 | 5 | 39.2% |
| Honoraria | $37,500 | 15 | 1.8% |
| Travel and Lodging | $36,463 | 79 | 1.8% |
| Consulting Fee | $35,682 | 14 | 1.8% |
| Food and Beverage | $8,038 | 311 | 0.4% |
Payments by Type
Research
$1.1M
8 transactions
General
$912,970
424 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| INdividualized ITI based on fviii ATE protection by vwf INITIATE | Octapharma USA, Inc. | $1.1M | 0 |
| Wil-20 | Octapharma USA, Inc. | $14,838 | 0 |
| wil-20 | Octapharma USA, Inc. | $3,600 | 0 |
Top Doctors Receiving Payments for WILATE — Page 9
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Pine Bluff, AR | $11.58 | 1 |
| , MD, MPH, MSCR | Neonatal-Perinatal Medicine | Morristown, NJ | $11.41 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Fort Smith, AR | $10.93 | 1 |
| , MD | Hematology & Oncology | Memphis, TN | $10.86 | 1 |
| , MD | Hematology & Oncology | Staten Island, NY | $10.85 | 1 |
Ad
Manufacturing Companies
- Octapharma USA, Inc. $2.0M
Product Information
- Type Biological
- Total Payments $2.0M
- Total Doctors 204
- Transactions 432
About WILATE
WILATE is a biological associated with $2.0M in payments to 204 healthcare providers, recorded across 432 transactions in the CMS Open Payments database. The primary manufacturer is Octapharma USA, Inc..
Payment data is available from 2017 to 2018. In 2018, $2.0M was paid across 259 transactions to 139 doctors.
The most common payment nature for WILATE is "Unspecified" ($1.1M, 55.0% of total).
WILATE is associated with 3 research studies, including "INdividualized ITI based on fviii ATE protection by vwf INITIATE" ($1.1M).